L-arginine decreases infarct size caused by middle cerebral arterial occlusion in SHR

Am J Physiol. 1992 Nov;263(5 Pt 2):H1632-5. doi: 10.1152/ajpheart.1992.263.5.H1632.

Abstract

L-Arginine, but not D-arginine, serves as a precursor for the synthesis of nitric oxide (NO), a potent dilator of cerebral blood vessels. We examined the effects of administering L-arginine (300 mg/kg ip) on the volume of infarction in two models of focal cerebral ischemia in spontaneously hypertensive rats (SHR). L-Arginine was administered before (16 and 3 h) and after (5 min and 2 h) vessel occlusion, and animals were killed 24 h later. L-Arginine treatment decreased infarct size in rats subjected to distal middle cerebral arterial (MCA) plus ipsilateral common carotid arterial (CCA) occlusion by 31% [147 +/- 12 (saline) vs. 101 +/- 9 mm3 (L-arginine), P < 0.05]. D-Arginine, administered according to the same dosage and protocol, was without effect. In the group subjected to proximal MCA occlusion, L-arginine decreased infarction size in the striatum by 28% [47 +/- 5 (saline) vs. 34 +/- 3 mm3 (L-arginine), P < 0.05] and neocortex by 11% [193 +/- 7 (saline) vs. 171 +/- 8 mm3 (L-arginine), P < 0.05]. Changes in blood pressure or other measured physiological parameters did not account for the observed differences. The possible use of L-arginine for the treatment of focal cerebral ischemia merits further investigation.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Arginine / pharmacology*
  • Arginine / therapeutic use
  • Brain Ischemia / complications*
  • Cerebral Infarction / drug therapy
  • Cerebral Infarction / etiology
  • Cerebral Infarction / pathology*
  • Hypertension / pathology
  • Male
  • Rats
  • Rats, Inbred SHR
  • Stereoisomerism
  • Vasodilation / drug effects*

Substances

  • Arginine